inclacumab   Click here for help

GtoPdb Ligand ID: 12312

Synonyms: HuMab 002 [2] | LC1004-002 | RO-4905417 | RO4905417
Immunopharmacology Ligand
Compound class: Antibody
Comment: Inclacumab (formerly RO4905417) is an IgG4κ monoclonal antobody that targets selectin P (CD62; SELP) [2] that was initially designed for potential to promote anti-inflammatory and antithrombotic effects as a mechanism to reduce atherosclerosis. It blocks the interaction between selectin P and its primary ligand, P-selectin glycoprotein ligand-1 (PSGL-1). Inclacumab was later repositioned to reduce vaso-occlusive crises in patients with sickle cell disease.
No information available.
Summary of Clinical Use Click here for help
Development in atherosclerosis has been terminated. Global Blood Therapeutics redirected development to determine the efficacy of inclacumab to reduce vaso-occlusive crises (VOCs) in sickle cell disease patients. The FDA granted orphan drug designation [1] and pediatric disease designation in mid-2022 which permits the use of inclacumab to treat patients with sickle cell disease.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04935879 A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Phase 3 Interventional Global Blood Therapeutics
NCT04927247 A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises Phase 3 Interventional Global Blood Therapeutics
NCT05348915 A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Phase 3 Interventional Global Blood Therapeutics